Tag Archives: pharma industry

Our experience on Adverse Drug Reactions (ADR) identification at TAC2017

MeaningCloud and LaBDA research group were present at the TAC 2017 conference held on November 13th – 14th at NIST headquarters in Washington. In the Text Analysis Conferences, research groups from all over the world were invited to develop software systems to tackle text analytics-related problems. This year, one task was devoted to the automatic identification of adverse drug reactions (ADRs) appearing in drug labels, including features defining the ADR, such as its severity or if it is characteristic of a drug class instead of just a given drug. There has been a specific subtask to link the identified ADRs with their corresponding MedDRA codes and lexical terms. More than 10 research teams have taken part in the project, all of them applying some kind of deep learning approach to the problem. Results show that it is possible to reach 85% accuracy when identifying ADRs.

We were delighted to present our text analytics-based system for ADRs identification on drug labels, which combines natural language processing and machine learning algorithms. The system has been built as a joint effort between MeaningCloud and LaBDA research group at the Universidad Carlos III de Madrid. Identifying ADRs is a basic task for pharmacovigilance, and that is the reason why the Federal Drug Administration (FDA) is involved in the funding and definition of the ADRs identification tasks in the framework of the Text Analysis Conferences. We have learned a lot these days (e.g., a BiLSTM deep neural network is the best choice for the purpose), and shared pleasant moments with our colleagues at Washington. We hope to be able to attend next year’s edition, which will focus on the extraction of drug-drug interactions (DDI), another interesting task aimed at detecting situations where the use of a combination of drugs may lead to an adverse effect.

Voice of the Patient Analysis in Forums

Voice of the Patient Analysis

In a previous post (Listening to the Voice of the Patient), we made an account of ongoing initiatives by public administration, hospitals and pharma companies intended to listen, understand and engage patients in the whole healthcare system. We also provided evidence that forums are a paramount source of information when talking about the Voice of the Patient Analysis.

As it was already shown, the Voice of the Patient (VoP) can be analyzed from multiple perspectives. In this post, we cover the point of view of the Pharma Industry.

Pharma Market Intelligence - Voice of the Patient

Continue reading

Listening to the Voice of the Patient

Voice of the Patient and Patient-Centered Health Care

National Library of Medicine

The modern definition of “patient centered health care” was stated in the National Library of Medicine’s MED-LINE subject heading (MeSH), introduced in 1995, which reads, “Design of patient care wherein institutional resources and personnel are organized around patients rather than around specialized departments.”

Following this design criterion, patients’ safety and well-being are the priority for all the agents involved in this industry: caregivers, pharmaceutical companies, medical device manufacturers, health insurers, and government agencies. And, being the center of our health systems, listening and engaging patients becomes the cornerstone of any quality improvement initiative. That’s why the so called “Voice of the Patient” is getting an increasing attention by all the stakeholders involved.

Continue reading